BioWisdom, a provider of solutions for accelerating access to scientific information for better decision support during product discovery, development and commercialization offers suite of software tools for the acquisition, integration, visualization and analysis of healthcare intelligence from an extensive collection of public and private sources.

Instem said that the acquisition has enhanced the launch of Centrus solution suite.

BioWisdom products will be marketed within Instem’s Centrus suite; complementing Instem’s focused capabilities for preclinical study data aggregation and delivery to allow a complete global view of data from discovery to the clinic.

Instem claims that following this acquisition, all of the world’s top 12 pharmaceutical companies and 16 of the top 20 will be Instem clients, as well as thousands of academic and not for profit researchers.

Instem CEO Phil Reason said integrating the BioWisdom products into Instem’s Centrus suite will significantly accelerate the introduction of new capabilities that focus on data integration, visual analytics and knowledge extraction.

BioWisdom CEO and Founder Gordon Baxter said the acquisition of BioWisdom by Instem creates opportunities for both companies in new but closely related markets.